- Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
-
Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU
- KMID: 2432263
- Chonnam Med J.
- 2019 Jan;55(1):73-73.
- doi: 10.4068/cmj.2019.55.1.73
The Acknowledgement was published incorrectly. -
- CITED
-
- Close
- SHARE
-
- Close
- Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
-
Lee SH, Jeon SW, Shin C, Pae CU, Patkar AA, Masand PS, An H, Han C
- KMID: 2530625
- Psychiatry Investig.
- 2022 Jun;19(6):500-500.
- doi: 10.30773/pi.2021.0368e
-
- CITED
-
- Close
- SHARE
-
- Close
- Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
-
Han Cs, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Mandelli L, Pae CU, Serretti A
- KMID: 2508991
- Clin Psychopharmacol Neurosci.
- 2020 Nov;18(4):641.
- doi: 10.9758/cpn.2020.18.4.641
-
- CITED
-
- Close
- SHARE
-
- Close
- Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective
-
Marks DM, Patkar AA, Masand PS, Pae CU
- KMID: 2315817
- Psychiatry Investig.
- 2009 Jun;6(2):55-58.
Pregabalin is a newly developed synthetic gamma-aminobutyric acid (GABA) that is approved for the treatment of fibromyalgia and several neuropathy. It has been proven to show analgesic, anxiolytic, anticonvulsant and... -
- CITED
-
- Close
- SHARE
-
- Close
- Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
-
Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU
- KMID: 2432266
- Chonnam Med J.
- 2016 Sep;52(3):159-172.
- doi: 10.4068/cmj.2016.52.3.159
Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has... -
- CITED
-
- Close
- SHARE
-
- Close
- Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
-
Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS
- KMID: 2519542
- Clin Psychopharmacol Neurosci.
- 2021 Aug;19(3):434-448.
- doi: 10.9758/cpn.2021.19.3.434
Antipsychotic monotherapy (APM) is considered best-acceptable treatment option regardless of antipsychotic class and formulation types for treating schizophrenia. However, antipsychotic polypharmacy (APP) has been also widely utilized in routine clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
-
Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU
- KMID: 2316423
- Psychiatry Investig.
- 2015 Apr;12(2):155-163.
- doi: 10.4306/pi.2015.12.2.155
We tried to review and update clinical and preclinical studies evaluating vilazodone's role as an antidepressant for patients with major depressive disorder (MDD). In terms of its mechanism of actions,... -
- CITED
-
- Close
- SHARE
-
- Close
- Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
-
Kim JJ, Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS
- KMID: 2522956
- Clin Psychopharmacol Neurosci.
- 2021 Nov;19(4):600-609.
- doi: 10.9758/cpn.2021.19.4.600
The mainstay of schizophrenia treatment is pharmacological therapy using various antipsychotics including first- and second-generation antipsychotics which have different pharmacokinetic and pharmacodynamic property leading to differential presentation of adverse events... -
- CITED
-
- Close
- SHARE
-
- Close
- Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
-
Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS
- KMID: 2502137
- Clin Psychopharmacol Neurosci.
- 2020 Feb;18(1):153-158.
- doi: 10.9758/cpn.2020.18.1.153
Objective: This study was done for collection of real world data of Aripiprazole Once Monthly (AOM) in patients with schizophrenia. Methods: The observation was up to 12 months from the first... -
- CITED
-
- Close
- SHARE
-
- Close
- Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder
-
Porcelli S, Pae CU, Han C, Lee SJ, Patkar AA, Masand PS, Balzarro B, Alberti S, De Ronchi , Serretti A
- KMID: 2316377
- Psychiatry Investig.
- 2014 Oct;11(4):481-486.
- doi: 10.4306/pi.2014.11.4.481
OBJECTIVE: The present study aimed to explore whether 4 single nucleotide polymorphisms (SNPs) within the AHI1 gene could be associated with major depressive disorder (MD) and bipolar disorder (BD), and... -
- CITED
-
- Close
- SHARE
-
- Close
- Vilazodone for the Treatment of Depression: An Update
-
Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU
- KMID: 2164318
- Chonnam Med J.
- 2016 May;52(2):91-100.
- doi: 10.4068/cmj.2016.52.2.91
Vilazodone is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitor and 5-HT(1A) receptor partial agonist profile, so it has been regarded as a serotonin partial agonist-reuptake inhibitor (SPARI).... -
- CITED
-
- Close
- SHARE
-
- Close
- The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
-
Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Pae CU
- KMID: 2464715
- Clin Psychopharmacol Neurosci.
- 2019 Nov;17(4):495-502.
- doi: 10.9758/cpn.2019.17.4.495
OBJECTIVE: The present study aimed to observe potential benefit of aripiprazole augmentation in the treatment of major depressive disorder with mixed specifier (MDDM) in naturalistic treatment setting. METHODS: Data were collected... -
- CITED
-
- Close
- SHARE
-
- Close
- Development of a Diverse Learning Experience for Diverse Psychiatry Resident Needs: A Four-Year Biological Psychiatry Curriculum Incorporating Principles of Neurobiology, Psychopharmacology, and Evidence-Based Practice
-
Muzyk AJ, Gagliardi , Rakesh G, Jiroutek M, Radhakrishnan R, Pae CU, Masand PS, Szabo ST
- KMID: 2378644
- Psychiatry Investig.
- 2017 May;14(3):289-297.
- doi: 10.4306/pi.2017.14.3.289
OBJECTIVE: A clinically relevant approach to patient care grounded in neurobiological constructs and evidence based practice which emphasizes a relevant psychopharmacology is needed to optimally train psychiatry residents. METHODS: We implemented... -
- CITED
-
- Close
- SHARE
-
- Close
- Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
-
Wang SM, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS, Pae CU
- KMID: 2411893
- Chonnam Med J.
- 2018 May;54(2):101-112.
- doi: 10.4068/cmj.2018.54.2.101
Randomized trials have shown that selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have better safety profiles than classical tricyclic antidepressants (TCAs). However, an increasing number of studies,... -
- CITED
-
- Close
- SHARE
-
- Close
- Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
-
Lee SH, Jeon SW, Shin C, Pae CU, Patkar AA, Masand PS, An H, Han C
- KMID: 2529257
- Psychiatry Investig.
- 2022 Apr;19(4):268-280.
- doi: 10.30773/pi.2021.0368
Objective This study aimed to compare the efficacy and safety of escitalopram, vortioxetine, and desvenlafaxine for acute treatment of major depressive disorder (MDD) with cognitive complaint (CC). Methods A total of... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
-
Shin C, Jeon SW, Lee SH, Pae CU, Hong N, Lim HK, Patkar AA, Masand PS, An H, Han C
- KMID: 2539658
- Clin Psychopharmacol Neurosci.
- 2023 Feb;21(1):135-146.
- doi: 10.9758/cpn.2023.21.1.135
Objective: Anxious depression is associated with greater chronicity, higher severity of symptoms, more severe functional impairment, and poor response to drug treatment. However, evidence for first-choice antidepressants in patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- ZNF804A Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders
-
Calabrò M, Mandelli L, Crisafulli C, Nicola MD, Colombo R, Janiri L, Lee SJ, Jun TY, Wang SM, Masand PS, Patkar AA, Han C, Pae CU, Serretti A
- KMID: 2502148
- Clin Psychopharmacol Neurosci.
- 2020 May;18(2):231-240.
- doi: 10.9758/cpn.2020.18.2.231
Objective: Genetic variations in the gene encoding zinc finger protein 804A gene (ZNF804A) have been associated with major depression and bipolar disorder. In this work we focused on the potential... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
-
Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS
- KMID: 2516175
- Clin Psychopharmacol Neurosci.
- 2021 May;19(2):233-242.
- doi: 10.9758/cpn.2021.19.2.233
Objective: In a number of controlled clinical trials and naturalistic studies, aripiprazole once monthly (AOM) has been found to be effective and safe as acute and maintenance treatment options for... -
- CITED
-
- Close
- SHARE
-
- Close
- Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1
-
Calabrò M, Mandelli L, Crisafulli C, Lee SJ, Jun TY, Wang SM, Patkar AA, Masand PS, Han C, Pae CU, Serretti A
- KMID: 2457399
- Clin Psychopharmacol Neurosci.
- 2019 Aug;17(3):364-368.
- doi: 10.9758/cpn.2019.17.3.364
OBJECTIVE: Genetics factors are likely to play a role in the risk, clinical presentation and treatment outcome in major depressive disorder (MDD). In this study, we investigated the role of... -
- CITED
-
- Close
- SHARE
-
- Close
- A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
-
Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Mandelli L, Pae CU, Serretti A
- KMID: 2428976
- Clin Psychopharmacol Neurosci.
- 2018 Nov;16(4):469-480.
- doi: 10.9758/cpn.2018.16.4.469
OBJECTIVE: Pharmacogenomic-based antidepressant treatment (PGATx) may result in more precise pharmacotherapy of major depressive disorder (MDD) with better drug therapy guidance. METHODS: An 8-week, randomized, single-blind clinical trial was conducted to... -
- CITED
-
- Close
- SHARE
-
- Close
